<p>India expects to get its first Johnson & Johnson Covid-19 vaccine doses from next month, filled and finished in India by a partner of the US drugmaker, a source with knowledge of the matter told Reuters on Monday.</p>.<p>It could receive as many as 43.5 million doses of the single-shot vaccine in October, said the source - a big step towards helping India meet its target of producing more than 300 million doses in the month.</p>.<p>India is the world's biggest centre of vaccine manufacturing. Once it has met its own needs, it plans to resume exports, which it stopped in April.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/india-to-resume-export-of-surplus-covid-19-vaccines-next-month-mandaviya-1032385.html" target="_blank">India to resume export of surplus Covid-19 vaccines next month: Mandaviya</a></strong></p>.<p>India's drug regulator last month gave emergency authorisation to the J&J vaccine, whether imported or locally filled and finished by J&J's Indian partner, Biological E.</p>.<p>However, the Indian government has not yet signed any supply deal with J&J.</p>.<p>"J&J doses are expected from next month," said the source, who declined to be named as he was not authorised to talk to the media. "Bio E will do the formulation and make 5 ml vials."</p>.<p>India's health ministry did not immediately respond to a request for comment.</p>.<p>A J&J India spokesperson said it was "premature for us to speculate on the timing of our vaccine deliveries". </p>.<p><strong>Check out DH's latest videos:</strong></p>
<p>India expects to get its first Johnson & Johnson Covid-19 vaccine doses from next month, filled and finished in India by a partner of the US drugmaker, a source with knowledge of the matter told Reuters on Monday.</p>.<p>It could receive as many as 43.5 million doses of the single-shot vaccine in October, said the source - a big step towards helping India meet its target of producing more than 300 million doses in the month.</p>.<p>India is the world's biggest centre of vaccine manufacturing. Once it has met its own needs, it plans to resume exports, which it stopped in April.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/india-to-resume-export-of-surplus-covid-19-vaccines-next-month-mandaviya-1032385.html" target="_blank">India to resume export of surplus Covid-19 vaccines next month: Mandaviya</a></strong></p>.<p>India's drug regulator last month gave emergency authorisation to the J&J vaccine, whether imported or locally filled and finished by J&J's Indian partner, Biological E.</p>.<p>However, the Indian government has not yet signed any supply deal with J&J.</p>.<p>"J&J doses are expected from next month," said the source, who declined to be named as he was not authorised to talk to the media. "Bio E will do the formulation and make 5 ml vials."</p>.<p>India's health ministry did not immediately respond to a request for comment.</p>.<p>A J&J India spokesperson said it was "premature for us to speculate on the timing of our vaccine deliveries". </p>.<p><strong>Check out DH's latest videos:</strong></p>